BPC 157 anti doping rules stay in force after HHS compounding policy

A federal decision to let pharmacies compound six unapproved peptides has not changed BPC 157 anti doping rules for licensed athletes, BoxingInsider reported on October 30. A Department of Health and Human Services policy says the government does not intend to act against pharmacies that compound BPC 157, TB 500, KPV, MOTS c, Epitalon and Semax under set conditions. Sports bans on all six still stand, the outlet said, and a prescription filled under the policy is no defense for a fighter who tests positive. None of the six peptides is approved by the FDA.

What the HHS peptide compounding policy allows

HHS released the interim policy on Wednesday, October 28, and the notice was published in the Federal Register on Friday, October 30, according to BoxingInsider. The document tells pharmacies with state licenses, federal facilities and licensed physicians that HHS "does not intend to take enforcement action" over compounding of the six peptides if they meet a set of conditions. That stance lasts until the FDA completes a formal rule on the 503A bulks list, the register of bulk substances pharmacies may use. The policy is not an approval. The HHS text states that the FDA does not check compounded drugs for safety, effectiveness or quality before they reach the market. Peptide Zone set out the core terms in its earlier report on the interim HHS compounding policy.

HHS framed the move as harm reduction. The policy says it will discourage the widespread use of "research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients" and calls pharmacy compounding under safeguards "a more controlled alternative." The conditions are detailed. Suppliers of the raw peptide must be registered with the FDA and must provide a certificate of analysis that tests identity, purity and potency and screens for endotoxins, heavy metals and microbes. Each product needs a prescription for a named patient. Serious adverse events and quality problems go to the FDA MedWatch system, and labels must state that the product is compounded and not for resale. Scott Brunner, chief executive of the Alliance for Pharmacy Compounding, said suppliers first need to show their ingredients meet the requirements, and "that may take time."

Why the WADA Prohibited List still applies

For athletes who compete under an anti doping code, the policy changes nothing, BoxingInsider said in an October 30 analysis written for licensed boxers. By its reading of the WADA Prohibited List, BPC 157 sits in class S0, the class for substances not currently approved for therapeutic use in humans, and it is the only one of the six the list names directly. TB 500, a synthetic fragment of the protein thymosin beta 4, is classed under S2 with peptide hormones and growth factors. MOTS c, a peptide encoded by mitochondrial DNA, is grouped under S4.4 with metabolic modulators. The outlet places Epitalon, KPV and Semax in S0 as well. Its own profile of Semax, however, says Russia has approved the peptide as a nasal spray, a detail the article does not reconcile with that class.

A pharmacy that may legally fill a prescription does not change the anti doping code a boxer accepts when a commission issues a license, the outlet said.

A pharmacy that may legally fill a prescription does not change the anti doping code a boxer accepts when a commission issues a license, the outlet said. VADA uses the WADA list, as do state commissions that test, BoxingInsider reported. A telehealth prescription does not count as a therapeutic use exemption, the outlet said, and a licensed boxer with a positive BPC 157 result in 2027 faces the same suspension that fighters have received this year. The article draws a line between patients and competitors. The HHS policy is written for patients who receive compounded peptides, while boxing commissions regulate fighters, who answer for everything found in their bodies no matter who signed the prescription. That leaves the BPC 157 anti doping position unchanged for anyone holding a license, and the outlet expects clinic advertising to grow.

Single ingredient and route limits

Two conditions shape what a pharmacy can dispense under the policy. Each product may contain "only a single Active Pharmaceutical Ingredient," BoxingInsider reported. That excludes the premixed blends that dominate online sales, including the BPC 157 and TB 500 pairing marketed as the Wolverine Stack and blends sold as GLOW and KLOW. Each of those two peptides could be compounded on its own, but they could not share a vial. The policy also fixes the route of use for each peptide. Semax is covered for intranasal use only, KPV for topical and oral use only, and TB 500, Epitalon and MOTS c for injection only. Only BPC 157 is covered across all four routes. The table sets out the routes and the anti doping classes as the outlet reported them.

The safety case HHS gives for each peptide is limited, based on the appendix passages the outlet quoted. For BPC 157, the appendix leans on "multiple human studies" and recorded use outside trials instead of controlled studies. For KPV, HHS says the objection from FDA staff reflects "an absence of information rather than an observed signal." For MOTS c, it points to a randomized trial with a placebo arm, testing a related analogue, that "reported no serious adverse events." For Semax, it cites an intranasal human record of "several hundred subjects" with no reported adverse outcome. For TB 500, it relies on the safety record of the parent protein. None of this amounts to the efficacy testing required for approval, a gap Peptide Zone examined in its review of the evidence behind the six.

The 503A bulks list fight and what comes next

The six peptides took a long route to this point, according to BoxingInsider. The FDA moved all six into Category 2, its group of bulk substances that "raise significant safety risks," in September 2023 and took them out on April 22, 2026. A July vote by the FDA Pharmacy Compounding Advisory Committee then backed listing them for 503A use. Agency scientists had argued in writing against all seven peptides on the agenda, and the panel rejected the seventh, emideltide. HHS says it "may revisit application of this interim policy" if a safety signal emerges. The policy ends once the FDA finalizes its rule, which could make the listing permanent or exclude the peptides. Five further peptides are due before the committee in February 2027.

Critics want the policy withdrawn. Jim Stansel, general counsel of the drug industry group PhRMA, said in a statement reported by BioSpace that allowing peptides without clinical trial proof of safety and effectiveness "jeopardizes patient safety." Robert Steinbrook of the Public Citizen Health Research Group called on HHS to withdraw it. According to Regulatory Focus, he said all peptide substances "should go through the standard FDA approval process for new drugs." Researchers at the Center for Science in the Public Interest argued in a JAMA Viewpoint that listing the peptides would give companies little reason to run trials. Brunner of the compounding alliance countered that patients already use these peptides and that the real question is where they get them.

Conclusion

HHS has opened a conditional, temporary path for pharmacies to compound six unapproved peptides, but the BPC 157 anti doping position for licensed athletes has not moved, according to BoxingInsider. The outlet reports that all six remain prohibited under the WADA framework that boxing testers follow. The next markers are the advisory committee meeting in February 2027 and the final FDA rule on the 503A list. Until then, the BPC 157 anti doping risk for any licensed competitor stays the same as before October 28.